Arbutus Biopharma Corp
NASDAQ:ABUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Indigo Exploration Inc
XTSX:IXI
|
CA |
|
Toro Co
NYSE:TTC
|
US |
|
K
|
Krynicki Recykling SA
WSE:KRC
|
PL |
|
S
|
Sapura Industrial Bhd
KLSE:SAPIND
|
MY |
|
MGIC Investment Corp
NYSE:MTG
|
US |
|
Agilyx AS
OTC:AGXXF
|
NO |
|
B
|
Beamr Imaging Ltd
NASDAQ:BMR
|
IL |
|
Geomatec Co Ltd
TSE:6907
|
JP |
Arbutus Biopharma Corp
Total Current Liabilities
Arbutus Biopharma Corp
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
Total Current Liabilities
$6m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Total Current Liabilities
$641.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
37%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
Arbutus Biopharma Corp
Glance View
Arbutus Biopharma Corp. is a biopharmaceutical company. The company is headquartered in Warminster, Pennsylvania and currently employs 85 full-time employees. The company went IPO on 2010-11-13. The firm is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, oral capsid inhibitor, an oral PD-L1 inhibitor, and oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The firm is having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses (including SARS-CoV-2).
See Also
What is Arbutus Biopharma Corp's Total Current Liabilities?
Total Current Liabilities
6m
USD
Based on the financial report for Dec 31, 2025, Arbutus Biopharma Corp's Total Current Liabilities amounts to 6m USD.
What is Arbutus Biopharma Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
-6%
Over the last year, the Total Current Liabilities growth was -62%. The average annual Total Current Liabilities growth rates for Arbutus Biopharma Corp have been -43% over the past three years , -9% over the past five years , and -6% over the past ten years .
